



Nature Precedings  is  to  enlist  constructive  criticism  from  the genomic and genetic community on the outlined approaches. The intent for the final version of this Vali‐dation Protocol (VP) is to become a useful standard by which to gauge the capabili‐ties of whole genome sequencing technologies that emerge even after 2012. The authors of this posting will moderate the discussion,  incorporate suitable sug‐gestions  and produce updated versions  from  time  to  time. We  intend  to  close  the discussion on or about April 15, 2011. Our intent is to publish the final version with as much community consensus as possible with all contributors to the final version being identified as such. In making  suggestions  please  keep  in mind  the  overriding  constraints  implicit  in such an endeavor: first, the final VP must be able to declare a winner or winners in the AGXP without controversy; second, any suggested changes should likely reduce the  actual  cost  of  carrying  out  the  physical  and  bioinformatic  procedures  of  the AGXP competition.  
I. Commentary and Definitions 
A. Goal:  This  document  provides  a  robust  and  routine  approach  to  evaluating  the  quality, accuracy and completeness of producing 100 human genome assemblies as part of                                                         1 J. Craig Venter Institute, Rockville Md. GSutton@jcvi.org 2 Genome Institute of Singapore, Agency 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Science, Technology and Research, Sin‐gapore. liue@gis.a‐star.edu.sg  3 National Center for Supercomputer Applications, 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Illinois. vjon‐gene@illinois.edu 4 CORRESPONDING AUTHOR: Department 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University 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the AGXP competition.  It is the intent of the X PRIZE Foundation that the process by which the contest will be judged be as transparent and open as possible.  
B. History of This Document This document is the collaborative work of many individuals led by Granger Sutton, Edison Liu, Victor Jongeneel, and Larry Kedes. The general scheme of the validation protocol has grown out of a larger scale effort to enlist the ideas and opinions of a number of bioinformatics and genomic sequencing experts. That process began with a summit workshop at the J. Craig Venter Institute in November 2008 and a second, larger meeting  at  the National  Center  for  Supercomputing Applications  (NCSA)  in March 2010. Lists of the attendees at those meetings appear in APPENDICES D and E.  
C. Uniqueness of the Archon Genomics X PRIZE (AGXP) for Sequencing:   The Sequencing requirements of the AGXP are unusual in respect to the complexity of  the  judging  criteria.   Many X PRIZE  competitions have a  singular  and definable threshold to be “crossed”: e.g. flying to the moon and returning, or staying aloft for X period of time. The threshold/boundary to be surpassed has further value:  i.e.,  the vessel can fly to Mars and back, or the vessel can stay aloft for X +1 period of time.  However, the sequencing for the AGXP has an “asymptotic” goal of achieving a defi‐nition of perfection.  With the human genome being a finite size and without a com‐pletely definitive standard of measuring this perfection, the judging is dependent on a definition of accuracy and completeness.   For  this reason, not only are clear and unequivocal  Test  Criteria  needed,  but  also  novel  judging  approaches  may  be  re‐quired (see below).       Though  the primary goal of  the AGXP  is  to  reward  the most advanced sequencing technologies, we are also aware that the judging process and criteria, and the mate‐rials used for judging (i.e., the DNA samples and cell lines, mapping and comparison algorithms) will be important standards for clinical sequencing.  Therefore, our goal will also be to develop protocols that can be used as industry benchmarks.   
D. Test Criteria:  There are three primary evaluation criteria and minimum standards for winning in any  category:  98%  completeness,  99.999%  accuracy  (1  error  per  100  kbp),  and production of a full diploid genome (2 complete copies of each chromosome except in the case of a male sample where single copies of the X and Y chromosomes will be provided).  Given that there are regions in the genome that remain impenetrable to contemporary sequencing, in defining the “denominator” for the accuracy and com‐pleteness criteria, we refer only to what is defined by the validation dataset. Lastly, the test criteria will be based on verifiable information extracted from the validation dataset,  and  not  from  the  currently  annotated  human  genome  sequence.    In  this manner data that we receive will be experimentally verified. 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The AGXP Rules require that each one of the 100 test genomes be sequenced by a competing Team to the same degree of accuracy and completeness. 
E. Definitions:   The  genomes  that  constitute  the  test  substrate will  be  called  the Test  Genomes.  The data  from which  completeness  and  accuracy will  be  judged will  be  called  the 




A. Approach We outline here approaches to a validation protocol that involves carefully choosing DNA samples and validation methods that will test the contestants’ capability to se‐quence and assemble genomes in a consistent, accurate, and unbiased manner. The validation methods are constrained by the assumption that validation costs should be a small fraction of the AGXP award.  For this reason, a sampling approach will be the  foundation  of  the  AGXP  Validation  Protocol  that  determines  the  Validation Dataset.  
B. AGXP Validation Protocol.  Experimental  validation methodologies  that  are  inexpensive,  robust  and  accurate and do not involve complete resequencing of some or all competition DNA samples must be established. A sampling approach will be used as a cost containment meas‐ure and to facilitate the analysis of a second sample set should one be required fol‐lowing one or more failed attempts.    
C. Deriving the Validation Dataset The Validation Dataset will be created by a sampling strategy using complementary technologies and judicious selection of DNA samples.  The technologies to generate the validation dataset will be: 
1. DNA  sample  selection  for  Haploid  Phasing,  structural  variants,  and  se‐quencing fidelity: selection of trios/quartets where parents will be included 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in the Test Genomes and progeny tested as part of the Validation Dataset. A single duplicate pair will be introduced in the Test Genomes to assess fidelity.  2. Random Fosmid  sequencing  for  haploid  phasing,  structural  variants,  and sequence fidelity 3. Targeted resequencing of highly polymorphic regions for sequence fidelity 4. Genotyping arrays appropriate for SNP and CNV calling for structural vari‐ants and sequence fidelity 5. Deep distant pair­end/mate­pair resequencing for structural variants These  techniques will be applied  to some, but not all of  the samples. The range of test genomes examined by each of the techniques as described below reflects three alternative sampling approaches with decreasing intensities of inclusion of test ge‐nomes  examined.  A  summary  of  the  three  alternative  validation  approaches  is  in APPENDIX  B.  The  choice  of  which  strategy  is  pursued  is  dependent  on  costs,  re‐sources and participation by technology centers and commercial vendors. A detailed summary of the three validation approaches can be found in APPENDIX C.  
D. DNA sample selection. A  predefined  set  of  100  human  DNA  sources—the  X  PRIZE  DNA  sample  Test  Ge­
nomes—will be used by contestants. As of this writing, these will be identified from the sample set available at the Coriell  Institute and will be chosen in the following manner: 
1. Related  samples  –  Parent‐child  trios  and  quartets will  be  employed  since haplotypes from a child should be found in each parent. The intent is to use these trios to ascertain the accuracy of the haplotypes produced for each dip‐loid genome. The production of full diploid genomes can be tested by the use of trios and quartets. The parents will be included in the 100 Test Genomes; the offspring(s) will be used  to  test  the phasing.   The progeny DNA will be withheld and not be included as Test Genomes, but will be used to derive the Validation Dataset.  At least four families will be engaged in this manner.     
2. Duplicated samples  – This provides a simple comparison  test of  the accu‐racy of  the sequencing and assembly processes.   This has as a complication the possible use of this information for internal correction by the contestants.  This however, can be resolved by the judging protocol. Manipulation of data 
by a contestant relying on the duplication would be discoverable.  3. Ancestral variability – Human genomes that exhibit varying degrees of se‐quence  and  structural  variation  and  of  recombination will  be  examined  by selecting  individuals with a  range of  ancestries  including  those expected  to have the shortest haplotype blocks with most recombination. 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E. Random fosmid sequencing validation5 The  rationale  for  determining  the  fosmid  sequencing  strategy  is  described  in APPENDIX A. Random clones  (fosmids) will be  isolated6  from 10  to 20 of  the 100 DNA samples. The number of  fosmids sequenced from each DNA sample will be at least  60007.  The  clones  from  each  individual  will  be  pooled  without  sample  bar‐coding of each fosmid clone and shotgun sequenced to deep (at least 50x) coverage. Only  clones  from  the  same DNA sample will be pooled. For determining sequence accuracy the reads will be aligned to the competitor’s sequence.  The  fact  that  fosmid  alignments  occur  in  localized ~40 KB  regions  of  the  genome will  guide  re‐assembly  of  the  sequence  reads.  All  runs  will  be  performed  using paired end minimum 75 bp reads– or longer as new methods emerge. This data set, after assembly of each fosmid and alignment of assembled fosmids to the reference genome, will enable characterization of many MB of diploid sequence  in each Test Genome. These data will serve as a template to compare the accuracy, completeness, and diploid assembly  (haploid phasing) of  contestant genome assemblies  for each cell line8. Any clone that cannot be reasonably aligned to the extant reference genomes (pos‐sibly including primates) would not be used for validation.  Such clones could be in‐cluded if their sequences can be verified present in other human genomes (e.g., by PCR analysis). 
F. Targeted sequencing via genome enrichment Targeted sequencing will be performed on the same  loci  in  the genome across be‐tween 50‐99 Test Genomes. Targeted loci (e.g. the HLA complex) will be selected on the basis of polymorphic complexity in the genome and in population samples. This                                                         5 The tests will be distributed with limited overlap so that no single sample will have excessive  weight  in  judging.    This  is  for  two  reasons;  first,  the  judging  may  be viewed as more fair if the samples for validation are distributed across the full set of 100, and second, in the event there is an error in a few samples, not all the valida‐tion criteria will be lost.  6 Fosmid library creation, clone picking, propagation and pooling can be done at any institution with a well developed capacity for working in a high throughput fashion with fosmids and clone picking. 7 The exact number of  fosmid clones will be determined by budgetary constraints and required scoring sensitivity. 8 One concern is artifacts in the clones such as rearrangements. We will address this concern by using the other validation methods as confirmation: where the clones do not  appear  to  align well  to  any  of  the  extant  reference  sequences  the  genotyping validation  can  be  used  to  confirm  some  SNP  variants  in  the  clones  and  the  long‐range paired‐end sequences to verify structural variants in the fosmid sequences. 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will  enable  the  ascertainment  of  sequencing  accuracy  of  contestant’s  genomes  in these regions. These loci will be enriched from each DNA sample and sequenced to generate ~100x average coverage per sample9. This is sufficient coverage to identify SNP and indels in these loci and will thus provide a measure of sequence accuracy in genomic loci bearing complex polymorphism. 
G. Genotyping validation We will assess haplotype‐sequencing accuracy at defined genomic loci via genotyp‐ing  in duplicate. Using the same platform and an additional reference DNA sample we will detect copy number variants (CNVs). We will determine for each test genome the sequence accuracy of at least 2.5 million common SNPs and all detectable CNVs. Each sample will be assessed twice to mini‐mize call errors and discordant results between duplicate runs will be discarded.10 
H. Digital Karyotyping or Pair­End maps.  Distant  pair‐end  sequencing  approaches  can  allow  for  deep  coverage  specifically targeting  the detection of  structural  variants.   A  single  sequencing  run on  a Next‐Generation instrument for a 10 KB distant pair end library will commonly provide 150X clonal  coverage  for a genome.    In  this manner,  the near nucleotide mapping rearrangement breakpoints will be assessed on a number of the DNA samples. Two libraries will be constructed: a 10kb gPET and a 1kb gPET  library  from 4, 6 or 10 test genomes. The fosmid and pair end libraries will not be created from the same genomes.     
                                                        9 In order to optimize sequencing throughput and reduce cost the enriched loci from each sample will be bar‐coded to retain sample identity. This will enable the pooling of the genomic enrichment products, minimize the number of Illumina machine runs required and  retain  sample  identity. Thus,  three machine  runs will  likely be  suffi‐cient to sequence all 100 samples generating paired end 75 bp reads. 10 This will  provide validation  that heterozygous variants between  the  two haplo‐types  are  being  accurately  detected  and  that  homozygous  variants  are  called  cor‐rectly. This would not be a good measure of the required 99.999% accuracy as the genotyping chips are not themselves that accurate. However, with the double geno‐typing chip requirement the accuracy will be 99.999%. 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III. Computational Validation and Scoring11 




B. Data Deposition and Format  The data on which the contestants will be judged will be for each analyzed genome a set of 46 sequence  files  in FASTA format, each containing the sequence of a single human chromosome. “N” characters will be used to represent undetermined nucleo‐tide positions or gaps in the assembly. The contestants are also required to submit raw  sequence  data  files  in  FASTQ  format  (or  equivalent). While  these will  not  be used  for  scoring  the  submissions,  they may  be  required  for  verification  purposes and in the case of a competitor challenge (see below). The data will be submitted to the AXGP Jury on two identical hard disks, each con‐taining a full set of files, to avoid potential data loss due to file corruption. The Jury will then hand them over to NCSA for comparison to the Validation Data and scor‐ing. 
C. Scoring12 Each one of the 100 genomic assemblies provided by the contestants must meet the Validation Criteria.  If any one of  the genomic assemblies provided by a contestant fails to meet any component of the Validation Criteria, then that contestant will have failed to meet the requirements of the Archon Genomics X PRIZE. The Validation Cri‐teria define thresholds for accuracy and for completeness. 
1. Accuracy A mismatch compared with the validation dataset is considered an error for the  purposes  of  calculating  accuracy.  The worst  2%  of  the  AGXP  clones  in terms of how well they align to the competitor’s sequence will not be used in that validation in order to avoid penalizing contestants for possible errors in the Validation Dataset.  a. A  rearrangement  or  haplotype  error  counts  as  one  error  but  insertion and deletion errors count the sum of each base in the indel. Missed inser‐tions  also  count  as  bases  missed  for  the  purposes  of  calculating  com‐pleteness (see below).  The score for accuracy will be derived from the following comparisons: 
o Alignments  between  the  competitor  sequences  and  the  fosmid  se‐quences in the Validation Dataset 
o Alignments  between  the  competitor  sequences  and  the  regions  that have been subjected to targeted resequencing 
o Matching of the competitor sequences to the SNP genotypes 
o Comparison  of  the  competitor  sequences  to  the  SNP  haplotypes  de‐termined from genotyping trios and quartets                                                         
12  The  computational  judging  protocols  will  primarily  be  automated  not  only  for speed but also for objectivity. 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D. Competitor challenges of validation results and retries The AGXP intends to minimize the jeopardy of revealing the validation dataset in the case of  a  challenge or  a  future  competition.   A  competitor will not have a  right  to challenge  the  decision  of  the  judges  but may  request  a  review.  A  competitor will have no access to the Validation Dataset either before or after a contest. The AGXP may,  at  its  sole discretion, make available  to  any  contestant  just  sufficient data  to demonstrate the reasons that their data failed to meet the validation criteria. Since any failure to meet completeness or accuracy goals must include a worst‐case sam‐ple that falls below the passing criteria, the XPRIZE Foundation need only share the data from this one cell line when defending a “fail” decision. Thus all other X PRIZE data can be kept as a secret. New samples will not have to be prepared for a second trial except as replacement of the sample whose data was shared.  The current rules call for competitors being charged for all costs related to a retry including samples, any new sequencing by X PRIZE, all judging costs, computational costs etc Clearly,  if  a  competitor maintained  the DNA  samples  or  passed  them along  to  an‐other  competitor  this  would  convey  an  unacceptable  advantage.  Contractual mechanisms will be placed in the Master Team Agreement to prevent this from oc‐curring. 
                                                        13  Completeness might  be  the most  contentious  as  a  competitor  could  argue  that many of the fosmid clones sequenced by AGXP fall in the 2% they are not required to cover.   The probability is VANISHINGLY SMALL that a competitor who indeed did sequence 98% of a given genome will have failed to sequence 98% of the AGXP se‐quences obtained from that genome. 
Appendix A: Derivation of Validation Datasets Prepared by Edison Liu, Pauline Ng, Anbupalam Thalamuthu, JianJun Liu, Hidetoshi Inoko Singapore Genetics Institute 


























0.00076  1315.789474  75  0.057  0.055405931  0.003069817 
African 
ancestry 
0.000994  1006.036217  75  0.07455  0.071838935  0.005160833 
European 
ancestry 
0.00076  1315.789474  150  0.114  0.107742044  0.011608348 
African 
ancestry 
0.000994  1006.036217  150  0.1491  0.138517038  0.01918697 












test genomes         
 SNP Array 
Capture 
Sequence 
Fosmid    
Sequence Distant Pair-end Library 
   (6000 clones) 10kb gPET 1kb gPET 
          
Validation I 149 99 20  10 10 
          
Validation II 131 75 12  6 6 
          
Validation III 119 50 10  4 4  
N fosmids    >10% overlap  Percent  >20% overlap  Percent  >50% overlap  Percent 500   0.0495 (0.0316)   0.25 (0.16)    0.0  495 (0.0316)   0.25 (0.16)   0.0373 (0.0269)   0.19 (0.13)  1000  0.2608 (0.0921)   0.65 (0.23)   0.2541 (0.0905)   0.64 (0.23)   0.2011 (0.0988)   0.50 (0.25)  2000  1.0451 (0.1601)   1.31 (0.20)   1.0126 (0.1746)   1.27 (0.22)   0.8026 (0.1733)   1.00 (0.22)  3000  2.4768 (0.1966)   2.06 (0.16)   2.4084 (0.202)   2.01 (0.17)   1.9323 (0.1580)   1.61 (0.13)  5000   6.4682 (0.3475)   3.23 (0.17)   6.2639 (0.3399)   3.13 (0.17)   4.7920 (0.3493)   2.40 (0.17) 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APPENDIX C: Summary of Three Validation Alternatives 
Validation Protocol I: One pair within the 100 test cases will be twins or the same cell line from the same individual. These will be used as "internal" controls and should yield near identical sequenced by the contestant.  Two samples will have had the full genome sequenced by two methods.  The overlap of the two technologies will be used as the validation dataset  96  test cases each as part of a  trio  (minus  fully sequenced genome and minus  the twins, and adjusted  for parentage).   Therefore  the adjunct cases will be N=48 and the total validation cases = 148  (100 + 48) All relevant validation cases (N=148) will be assessed for SNPs as part of the test for sequence accuracy, for completeness, and for phasing.   A 2.5 million SNP assay de‐vice will be used X2 and the concurrent SNPs will be used in the assessment.  Phas‐ing will be calculated on the samples All test cases (N=98) will be assessed by capture sequencing of the HLA locus to test for sequence accuracy.  Approximately 3.8Mb will be sequenced at 50‐70X coverage.  20  test cases will be assessed by  fosmid sequencing  for phasing,  for accuracy, and for completeness.  6000 clones will be sequenced per individual.  Together this will mean 4.8 Gb will be sequenced 10  genomes will  be  assessed by distant  pair  end  libraries  to  assess  private  struc‐tural variants.  Each will be assessed by a 10Kb gPET library sequenced to 100‐150X coverage, and a 1kb gPET library at 100X coverage.      
 
Validation Protocol II: One pair within the 100 test cases will be twins or the same cell line from the same individual. These will be used as "internal" controls and should yield near identical sequenced by the contestant.  One sample will have had the full genome sequenced by two methods.  The overlap of the two technologies will be used as the validation dataset.   60 test cases will be part of a trio.  Therefore the adjunct cases will be N=30 and the total validation cases = 130 All  validation  cases  (N=130) will  be  assessed  for  SNPs  as  part  of  the  test  for  se‐quence accuracy, for completeness, and for phasing.  A 2.5 million SNP device will be used X2 and  the concurrent SNPs will be used  in  the assessment.   Phasing will be calculated on the samples 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75% of the test cases (N=75) will be assessed by capture sequencing of the HLA lo‐cus  to  test  for  sequence accuracy.   Approximately 3.8Mb will be  sequenced at 50‐70X coverage.  12  test cases will be assessed by  fosmid sequencing  for phasing,  for accuracy, and for completeness.  6000 clones will be sequenced per individual.  Together this will mean 2.9 Gb will be sequenced. 6 genomes will be assessed by distant pair end libraries to assess private structural variants.  Each will be assessed by a 10Kb gPET library sequenced to 100‐150X cov‐erage, and a 1kb gPET library at 100X coverage.    
 




NAME  AFFILIATION  TITLE Mark Adams  Case Western Reserve University  Associate Professor PhD Training Faculty Richa Agarwala  NIH  – NLM  (National  Library  of Medi‐cine)   Computational Biologist Serafim Batzoglou   Stanford  Associate Professor 
Michael Brudno  University of Toronto  Assistant  Professor  &  Canada  Research  Chair Computational Biology Deanna M.Church  DHHS/NIH/NLM/NCBI  Staff Scientist Research Fellow Rod Corriveau   Coriell Institute  Assoc Prof & Scientific Program Manager for the Coriell Cell Repositories Robert Holt  BC  Cancer  Research  Centre  –  Genome Sciences Centre  Head, Sequencing, Genome Sciences Centre David Jaffe,  Broad – Genome Biology Program  Director, Computational R&D 
Steven Scherer  The Centre for Applied Genomics The Hospital for Sick Children  Director Larry Kedes    Sr. Advisor and Scientific Director 
Andrew Wooten   X PRIZE Foundation  Senior Director, Archon Genomics X Prize  
Barry Thompson  X PRIZE Foundation  Tervela Founder and CTO  Sam Levy   J. Craig Venter Institute  Director, Human Genomics  Yu‐Hui Rogers  J. Craig Venter Institute  Vice President of Core Technology Granger Sutton  J. Craig Venter Institute  Sr. Director, Informatics  
 APPENDIX E:  Attendees Bioinformatics Workshop 
NCSA (March 2010) 
  Name  Organization Bernie A'cs  NCSA Loretta Auvil  NCSA Serafim Batzoglou  Stanford Chris Beitel  NCSA Guillaume Bourque  ASTAR Deanna M. Church  DHHS/NIH/NLM/NCBI Andrew Davis   Monsanto Thom Dunning  NSCA Jennifer Eardley  UIUC Adam Felsenfeld  NIH/NHGRI Aaron Halpern  Complete Genomics Jill Herschleb  Halcyon Molecular Tim Hunkapillar  Discovery Biosciences Victor Jongeneel  NCSA/UIUC Scott Kahn  Illumina Larry Kedes  X PRIZE Foundation Jim Knight   454 Life Sciences Denis Larkin  UIUC Sam Levy  Scripps Health, San Diego Harris Lewin  UIUC Cristin Lindsay  X PRIZE Foundation Ed Liu  HUGO Havier Llora  NCSA Jian Ma  UIUC Elizabeth Mansfield  FDA Francisco "Paco" Martinez‐Murillo  FDA Luke Nosek  Halcyon Molecular Danny Powell  NCSA Don Preuss  NIH/NCBI Steve Skienna  Stony Brook David Smith  Mayo Clinic Jonathan Stark  Halcyon Molecular Granger Sutton  J. Craig Venter Institute Mike Welge  NCSA David Tcheng  NCSA 
